Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Larsen

Interventional Pain Medicine Saint George, UT Medical Doctor

NPI 1235579731 CMS profile 7080179

617 E Riverside Dr Ste 301, Saint George, UT 84790

Open in the dashboard

General payments

$14,216

350 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Larsen of Saint George, UT is reported in the CMS Open Payments database as having received $14,216 across 350 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,021 66
2024 General $2,941 55
2023 General $3,523 78
2022 General $1,541 67
2021 General $1,632 61
2020 General $1,049 16
2019 General $510 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Larsen
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Steven Larsen were reported at $3,021. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Steven Larsen Interventional Pain Medicine median Middle half National median
2019 $510 $684 $216–$2,079 $163
2020 $1,049 $382 $122–$1,109 $114
2021 $1,632 $552 $167–$1,554 $132
2022 $1,541 $605 $187–$1,924 $149
2023 $3,523 $671 $195–$1,915 $160
2024 $2,941 $684 $206–$1,837 $164
2025 $3,021 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,663 79 payments
  2. Medtronic, Inc. $3,069 56 payments
  3. Nalu Medical, Inc. $2,493 24 payments
  4. Nevro Corp. $1,426 59 payments
  5. AbbVie, Inc. $511 25 payments
  6. SPR Therapeutics, Inc $382 8 payments
  7. Relievant Medsystems, Inc. $323 10 payments
  8. Abbott Laboratories $275 7 payments
  9. Stimwave Technologies Incorporated $189 1 payment
  10. GlaxoSmithKline, LLC. $154 9 payments
  11. Other $1,731 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,560 330 payments
  2. Travel and Lodging $4,656 20 payments
Products named General payments · program years 2019–2025
  1. Nalu Neurostimulation System $2,493 24 payments
  2. SYNCHROMEDII $1,800 17 payments
  3. Artisan $790 20 payments
  4. KYPHON EXPRESS II KYPHOPAK TRAY $672 6 payments
  5. INTELLIS ADAPTIVESTIM $539 27 payments
  6. Omnia $481 37 payments
  7. VERTIFLEX SUPERION $424 2 payments
  8. Senza $388 13 payments
  9. SPRINT PNS System $382 8 payments
  10. General - Pain Management $377 12 payments
  11. Other $6,564 196 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

541

Median for Pain Management: 951

Drug cost

$8,101

Median for Pain Management: $26,034

Branded share of claims

42.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 80 $2,464
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 138 $2,233
Oxycodone Hcl Generic 25 $687
Gabapentin Generic 38 $568
Tramadol Hcl Generic 79 $531
Cephalexin Generic 50 $407
Cyclobenzaprine Hcl Generic 31 $326
Pregabalin Generic 33 $281
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 11 $197
Duloxetine Hcl Generic 14 $197

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$484,982

Of which drugs: $15,345

Medicare patients

686

Average age 75

Services billed

11,140

367 women, 319 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Depression 34%
Ischemic heart disease 27%
Diabetes 24%
Chronic kidney disease 24%
Osteoporosis 17%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 11 672 $4,748
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 528 5,568 $4,272
Injection, fentanyl citrate, 0.1 mg J3010 Office 85 104 $75
Injection, midazolam hydrochloride, per 1 mg J2250 Office 96 250 $26
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 22 207 $18
Injection, ketorolac tromethamine, per 15 mg J1885 Office 11 15 $8
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 17 71 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $62
$62 — —
BOTOX
  • AbbVie, Inc. $57
$57 — —
Qutenza
  • Averitas Pharma Inc. $39
$39 — —
QULIPTA
  • AbbVie, Inc. $33
$33 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record